Covered recipient · General Payments record
HUMAM W FARAH
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$140,947.82
250 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,633.09 | 32 |
| Honoraria | $51,000.00 | 11 |
| Travel and Lodging | $15,321.97 | 46 |
| Consulting Fee | $5,580.00 | 3 |
| Food and Beverage | $5,257.78 | 156 |
| Education | $154.98 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 5 of 5; records 201–250 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HUMAM W FARAH
NPI 1306880141 · CMS profile ID 13577
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
HANNIBAL, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–250 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1306880141?year=2025&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HUMAM W FARAH, NPI 1306880141, CMS profile ID 13577. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–250 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306880141?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). HUMAM W FARAH, NPI 1306880141, CMS profile ID 13577. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–250 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306880141?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- HUMAM W FARAH, NPI 1306880141, CMS profile ID 13577, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–250 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1306880141?year=2025&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
250 matching records · $140,947.82 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 250.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Verona Pharma, Inc. | $9.05 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754143 | CMS |
| JAZZ PHARMACEUTICALS INC. | $16.50 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234342288 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.15 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223809492 | CMS |
| HARMONY BIOSCIENCES LLC | $17.72 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222391562 | CMS |
| Verona Pharma, Inc. | $1,500.00 | 02/27/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754285 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.47 | 02/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206425941 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,250.00 | 02/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206422945 | CMS |
| Viatris Specialty LLC | $132.55 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238497823 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $3.21 | 02/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223799992 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $11.02 | 02/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223806696 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.12 | 02/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223833717 | CMS |
| AstraZeneca Pharmaceuticals LP | $133.00 | 02/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206721309 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.65 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206758024 | CMS |
| Verona Pharma, Inc. | $186.61 | 02/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754275 | CMS |
| Verona Pharma, Inc. | $337.40 | 02/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754277 | CMS |
| Verona Pharma, Inc. | $121.70 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754279 | CMS |
| Verona Pharma, Inc. | $5,000.00 | 02/20/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754283 | CMS |
| AstraZeneca Pharmaceuticals LP | $950.00 | 02/19/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206801508 | CMS |
| Viatris Specialty LLC | $22.99 | 02/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238511291 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,049.00 | 02/11/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223794466 | CMS |
| Olympus Corporation of the Americas | $46.14 | 02/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1220570609 | CMS |
| Olympus Corporation of the Americas | $330.80 | 02/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1220570615 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.82 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222951657 | CMS |
| Verona Pharma, Inc. | $122.01 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754267 | CMS |
| Verona Pharma, Inc. | $132.13 | 01/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754269 | CMS |
| Verona Pharma, Inc. | $314.21 | 01/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754271 | CMS |
| Verona Pharma, Inc. | $458.96 | 01/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754273 | CMS |
| Verona Pharma, Inc. | $5,000.00 | 01/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754281 | CMS |
| Actelion Pharmaceuticals US, Inc. | $12.40 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174245045 | CMS |
| HARMONY BIOSCIENCES LLC | $16.69 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222391526 | CMS |
| Olympus Corporation of the Americas | $22.72 | 01/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1220570611 | CMS |
| Olympus Corporation of the Americas | $23.06 | 01/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1220570613 | CMS |
| Verona Pharma, Inc. | $19.32 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754151 | CMS |
| Novo Nordisk Inc | $14.05 | 01/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188861046 | CMS |
| Viatris Specialty LLC | $1,702.25 | 01/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238483883 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.25 | 01/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223933452 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.12 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206757426 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $61.52 | 01/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223939875 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $116.33 | 01/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223941004 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $87.10 | 01/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224097268 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,024.80 | 01/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224098848 | CMS |
| Verona Pharma, Inc. | $14.61 | 01/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233754149 | CMS |
| HARMONY BIOSCIENCES LLC | $16.19 | 01/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222391486 | CMS |
| Kowa Pharmaceuticals America, Inc. | $14.59 | 01/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243086790 | CMS |
| AstraZeneca Pharmaceuticals LP | $57.72 | 01/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206988649 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,485.00 | 01/07/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223794033 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $6,831.00 | 01/07/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223794652 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $43.24 | 01/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223939256 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $36.00 | 01/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224096918 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $87.10 | 01/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224097266 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $448,936.97 | 95 |
| PY2024 | Principal investigator | $373,396.41 | 90 |
| PY2023 | Principal investigator | $339,821.24 | 65 |
| PY2022 | Principal investigator | $338,256.33 | 25 |
| PY2021 | Recipient | $150.00 | 1 |
| PY2021 | Principal investigator | $108,561.52 | 5 |
| PY2020 | Principal investigator | $235,197.34 | 25 |
| PY2019 | Principal investigator | $57,964.10 | 63 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
95 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,032.80 | 12/22/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226124635 |
| Principal investigator 1 | Genentech, Inc. | $1,801.00 | 12/17/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211601555 |
| Principal investigator 1 | Genentech, Inc. | $1,313.00 | 12/17/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211601614 |
| Principal investigator 1 | Genentech, Inc. | $1,313.00 | 12/17/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211601628 |
| Principal investigator 1 | Genentech, Inc. | $450.00 | 12/16/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211611859 |
| Principal investigator 1 | Genentech, Inc. | $375.00 | 12/16/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211611863 |
| Principal investigator 1 | Genentech, Inc. | $458.00 | 12/16/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211611868 |
| Principal investigator 1 | Genentech, Inc. | $675.00 | 12/11/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211611842 |
| Principal investigator 1 | Genentech, Inc. | $396.00 | 12/11/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211611846 |
| Principal investigator 1 | Genentech, Inc. | $375.00 | 12/11/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211611850 |
| Principal investigator 1 | Genentech, Inc. | $585.00 | 12/11/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211611854 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,300.00 | 12/08/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226124639 |
| Principal investigator 1 | United Therapeutics Corporation | $350.00 | 12/02/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385675 |
| Principal investigator 1 | Genentech, Inc. | $788.00 | 11/21/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211601511 |
| Principal investigator 1 | Genentech, Inc. | $77.00 | 11/19/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211601535 |
| Principal investigator 1 | Genentech, Inc. | $5,866.00 | 11/18/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611932 |
| Principal investigator 1 | Genentech, Inc. | $2,600.00 | 11/12/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211611907 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,313.00 | 11/07/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM, INC | Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185554783 |
| Principal investigator 1 | United Therapeutics Corporation | $600.00 | 11/07/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385687 |
| Principal investigator 1 | United Therapeutics Corporation | $800.00 | 11/07/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385689 |
| Principal investigator 1 | United Therapeutics Corporation | $1,100.00 | 11/07/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385691 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 11/04/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226124631 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,608.00 | 10/27/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226124629 |
| Principal investigator 1 | Genentech, Inc. | $2,763.00 | 10/21/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211611830 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 10/14/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611813 |
| Principal investigator 1 | Genentech, Inc. | $3,153.80 | 10/14/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611818 |
| Principal investigator 1 | Genentech, Inc. | $1,008.00 | 10/14/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611822 |
| Principal investigator 1 | Genentech, Inc. | $2,556.00 | 10/14/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611833 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 10/14/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611838 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,881.70 | 10/14/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226124625 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 10/08/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211611903 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,400.00 | 10/06/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226124615 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,050.00 | 10/06/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226124619 |
| Principal investigator 1 | United Therapeutics Corporation | $3,217.65 | 10/06/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385707 |
| Principal investigator 1 | Genentech, Inc. | $1,926.00 | 10/02/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211611826 |
| Principal investigator 1 | United Therapeutics Corporation | $448.00 | 09/25/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385685 |
| Principal investigator 1 | United Therapeutics Corporation | $2,571.00 | 09/25/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385697 |
| Principal investigator 1 | United Therapeutics Corporation | $3,019.00 | 09/25/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385701 |
| Principal investigator 1 | United Therapeutics Corporation | $3,019.00 | 09/25/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385705 |
| Principal investigator 1 | United Therapeutics Corporation | $13,300.00 | 09/25/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385717 |
| Principal investigator 1 | United Therapeutics Corporation | $13,300.00 | 09/25/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385719 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $427.92 | 09/24/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH, INC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185554785 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,655.10 | 09/15/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226124610 |
| Principal investigator 1 | Genentech, Inc. | $7,395.00 | 09/11/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611919 |
| Principal investigator 1 | Genentech, Inc. | $1,926.00 | 09/02/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211611924 |
| Principal investigator 1 | Genentech, Inc. | $10,567.00 | 08/21/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611915 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,031.00 | 08/14/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults | No dispute reported | 06/30/2026 | 1232940097 |
| Principal investigator 1 | Genentech, Inc. | $18,190.00 | 08/05/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211611928 |
| Principal investigator 1 | United Therapeutics Corporation | $448.00 | 07/31/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385683 |
| Principal investigator 1 | United Therapeutics Corporation | $3,019.00 | 07/31/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385703 |
| Principal investigator 1 | United Therapeutics Corporation | $13,300.00 | 07/31/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385721 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $600.00 | 07/21/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226124607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,205.70 | 07/14/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226124603 |
| Principal investigator 1 | United Therapeutics Corporation | $6,435.30 | 07/04/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385713 |
| Principal investigator 1 | Genentech, Inc. | $3,258.00 | 07/02/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211611898 |
| Principal investigator 1 | Genentech, Inc. | $1,584.00 | 06/04/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211611894 |
| Principal investigator 1 | Genentech, Inc. | $1,180.00 | 05/28/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211601324 |
| Principal investigator 1 | Genentech, Inc. | $325.00 | 05/28/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211601343 |
| Principal investigator 1 | Genentech, Inc. | $2,100.00 | 05/28/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211601355 |
| Principal investigator 1 | Genentech, Inc. | $309.00 | 05/27/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611787 |
| Principal investigator 1 | Genentech, Inc. | $30,734.00 | 05/27/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611790 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 05/27/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611799 |
| Principal investigator 1 | United Therapeutics Corporation | $448.00 | 05/15/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385679 |
| Principal investigator 1 | United Therapeutics Corporation | $2,571.00 | 05/15/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385695 |
| Principal investigator 1 | United Therapeutics Corporation | $3,019.00 | 05/15/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385699 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,847.00 | 05/14/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults | No dispute reported | 06/30/2026 | 1232940095 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 05/13/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611804 |
| Principal investigator 1 | Genentech, Inc. | $23,024.00 | 05/06/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211611808 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,887.00 | 05/05/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226124594 |
| Principal investigator 1 | Genentech, Inc. | $9,032.00 | 04/22/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE S | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | No dispute reported | 06/30/2026 | 1211611795 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,600.00 | 04/14/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226124599 |
| Principal investigator 1 | Genentech, Inc. | $2,758.00 | 04/09/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211601360 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,550.00 | 04/07/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226124587 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,426.10 | 04/07/2025 | Non-covered Recipient Entity Vantage Clinical Trials Llc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226128570 |
| Principal investigator 1 | United Therapeutics Corporation | $400.00 | 04/07/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385677 |
| Principal investigator 1 | United Therapeutics Corporation | $448.00 | 04/07/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385681 |
| Principal investigator 1 | United Therapeutics Corporation | $2,571.00 | 04/07/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385693 |
| Principal investigator 1 | United Therapeutics Corporation | $6,038.00 | 04/07/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385711 |
| Principal investigator 1 | United Therapeutics Corporation | $26,600.00 | 04/07/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385723 |
| Principal investigator 1 | United Therapeutics Corporation | $8,341.95 | 04/04/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385715 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,463.00 | 04/02/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226124582 |
| Principal investigator 1 | Genentech, Inc. | $792.00 | 03/21/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211611883 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $20,000.00 | 03/17/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226124572 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $5,465.30 | 03/12/2025 | Non-covered Recipient Entity BLESSING CORPORATE SERVICES INC. DBA BLESSING HEALTH SYSTEM | Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype | No dispute reported | 06/30/2026 | 1214125502 |
| Principal investigator 1 | Genentech, Inc. | $1,905.00 | 03/03/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211601236 |
| Principal investigator 1 | Genentech, Inc. | $1,584.00 | 02/28/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211611878 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,948.00 | 02/18/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226124577 |
| Principal investigator 1 | Genentech, Inc. | $792.00 | 02/12/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211611887 |
| Principal investigator 1 | Genentech, Inc. | $36,333.00 | 02/06/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211611911 |
| Principal investigator 1 | Genentech, Inc. | $792.00 | 01/31/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211611873 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,688.00 | 01/21/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226124568 |
| Principal investigator 1 | Genentech, Inc. | $1,300.00 | 01/17/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211601191 |
| Principal investigator 1 | Genentech, Inc. | $1,180.00 | 01/17/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211601268 |
| Principal investigator 1 | Genentech, Inc. | $2,376.00 | 01/13/2025 | Non-covered Recipient Entity HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211611890 |
| Principal investigator 1 | United Therapeutics Corporation | $4,528.65 | 01/09/2025 | Non-covered Recipient Entity Hannibal Regional Healthcare System | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242385709 |